A Study to Evaluate Effectiveness and Safety of Deucravacitinib in Participants With Non-Pustular Palmoplantar and Genital Psoriasis

Part of paid clinical trials in Phoenix, Arizona.

Sponsor
Bristol-Myers Squibb
Study ID
NCT06042920
Phase
PHASE4
Status
Terminated

Conditions

  • Genital Psoriasis
  • Palmoplantar Psoriasis

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Deucravacitinib — DRUG
    Specified dose on specified days
  • Placebo — DRUG
    Specified dose on specified days

Study Details

The purpose of this study is to measure the safety and effectiveness of deucravatinib in participants with non-pustular palmoplantar psoriasis and genital psoriasis.

Key Dates

Start date
Oct 9, 2023
Status verified
Mar 2026
Primary completion
Apr 25, 2025
Completion
Apr 25, 2025

Study Design

Enrollment
130 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Deucravacitinib
  • Placebo Comparator: Placebo followed by Deucravacitinib

Primary Outcome Measure

Percentage of Participants Achieving Palmoplantar Psoriasis Area and Severity Index (Pp-PASI)-75 Response [ Time Frame: Week 16 ]

Locations (20)

FacilityCityStateZIPSite coordinators
Local Institution - 0050PhoenixArizona85006-2722-
Local Institution - 0015Fountain ValleyCalifornia92708-
Local Institution - 0009Los AngelesCalifornia90045-3606-
Local Institution - 0004Santa MonicaCalifornia90404-
Local Institution - 0057SkokieIllinois60077-1049-
Local Institution - 0052IndianapolisIndiana46250-
Local Institution - 0053PlainfieldIndiana46168-2792-
Local Institution - 0029RockvilleMaryland20850-6243-
Local Institution - 0012DetroitMichigan48202-3141-
Local Institution - 0005East WindsorNew Jersey08520-2505-
Local Institution - 0002New YorkNew York10003-
Local Institution - 0008New YorkNew York10075-
Local Institution - 0062New YorkNew York10128-
Local Institution - 0001Winston-SalemNorth Carolina27157-
Local Institution - 0066BoardmanOhio44512-
Local Institution - 0055Mayfield HeightsOhio44124-4005-
Local Institution - 0056PittsburghPennsylvania15213-3403-
Local Institution - 0010HoustonTexas77004-
Local Institution - 0007NorfolkVirginia23502-3933-
Local Institution - 0033Mill CreekWashington98012-1797-

Related coverage on Hipa.ai

Find similar trials in Phoenix, AZ

By research site
Local Institution - 0050· Phoenix, AZLocal Institution - 0015· Fountain Valley, CALocal Institution - 0009· Los Angeles, CALocal Institution - 0004· Santa Monica, CALocal Institution - 0057· Skokie, ILLocal Institution - 0052· Indianapolis, IN